Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on Antidiabetic Regimens Either Including no Insulin, or With Basal Insulin as Their Only Insulin

NCT02320721 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02320721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02320721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on Antidiabetic Regimens Either Including no Insulin, or With Basal Insulin as Their Only Insulin
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2015
Completion date
May 31, 2016
Enrollment
1,014 (actual)
Sites
162

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus